How to Get Jardiance in Tennessee: Prescriptions, Telehealth, and Pharmacy Access

What Is Jardiance and Why Tennessee Patients Are Seeking It

Jardiance is an FDA-approved sodium-glucose cotransporter-2 (SGLT2) inhibitor containing 10 mg or 25 mg empagliflozin per tablet, taken once daily in the morning. Beyond glucose control, the drug carries three distinct FDA indications, a range that no other oral diabetes agent matched at its approval. That breadth is why prescriptions in Tennessee have grown steadily since the landmark EMPA-REG OUTCOME trial published in the New England Journal of Medicine in 2015.

The FDA first approved empagliflozin for type 2 diabetes glycemic control in August 2014 [1]. The agency later approved it to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, based on EMPA-REG OUTCOME data [2]. A third indication for heart failure with reduced ejection fraction followed in 2021, and a fourth for chronic kidney disease with proteinuria arrived in 2023, supported by the EMPA-KIDNEY trial (N=6,609) [3]. Each new indication created a new group of Tennessee patients who might benefit.

In EMPA-REG OUTCOME (N=7,020), empagliflozin 10 mg or 25 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 14% versus placebo (hazard ratio 0.86; 95% CI 0.74-0.99; P<0.001 for non-inferiority, P=0.04 for superiority) [2]. Cardiovascular death alone fell by 38% [2]. These figures explain why the 2023 American Diabetes Association Standards of Care recommend SGLT2 inhibitors for patients with type 2 diabetes and established ASCVD, heart failure, or CKD independent of A1c [4].

Tennessee's diabetes burden adds local urgency. The CDC reports Tennessee has an age-adjusted diabetes prevalence of 13.3%, placing the state among the top ten nationally [5]. Roughly 800,000 Tennesseans are living with diagnosed diabetes [5], and a meaningful share qualify for empagliflozin based on cardiovascular or kidney comorbidities alone.

Who Can Prescribe Jardiance in Tennessee

Any licensed Tennessee prescriber with DEA registration and a valid prescribing relationship may write for Jardiance. That group includes physicians (MD, DO), nurse practitioners exercising independent prescribing authority, and physician assistants practicing under a collaborative agreement.

Tennessee enacted full practice authority for advanced practice registered nurses under Tenn. Code Ann. § 63-7-123, meaning a Tennessee-licensed NP may prescribe Jardiance without physician co-signature [6]. Physician assistants in Tennessee operate under a supervision agreement, but that agreement does not require the physician to co-sign every prescription. In practice, both NPs and PAs at telehealth companies regularly initiate Jardiance for qualifying patients in this state.

The prescriber must document a valid clinical relationship. Tennessee law, consistent with the federal Ryan Haight Act, generally requires either an in-person examination or a synchronous audio-video telehealth encounter before issuing a controlled substance. Empagliflozin is not a controlled substance, so it may be prescribed after a synchronous audio-video visit or, in many telehealth platforms, an asynchronous visit that reviews labs, photos of prior prescriptions, and a structured medical questionnaire. Confirm the platform's specific workflow before booking.

The American Association of Clinical Endocrinology 2023 guidelines note that SGLT2 inhibitor prescribing should involve eGFR assessment at baseline because efficacy drops substantially below eGFR 45 mL/min/1.73m² and the drug is generally not initiated below eGFR 30 [7]. Tennessee prescribers across all license types are expected to follow those thresholds.

Labs Required Before a Jardiance Prescription in Tennessee

Before any Tennessee provider writes for empagliflozin, they will review three categories of lab data. Getting these drawn in advance cuts the time between your first visit and an active prescription.

Basic metabolic panel (BMP). The BMP supplies serum creatinine, from which the estimated glomerular filtration rate (eGFR) is calculated. Empagliflozin is not recommended when eGFR falls below 30 mL/min/1.73m² [1]. At eGFR 30-44, the drug may be continued in patients already taking it for kidney or heart failure indications, but new prescriptions at that range require careful documentation of rationale [7].

Urine albumin-to-creatinine ratio (UACR). This test identifies patients with diabetic kidney disease, a group that sees the greatest absolute risk reduction from empagliflozin. In the CREDENCE trial (N=4,401) using canagliflozin (a related SGLT2 inhibitor), the relative risk of the primary composite kidney outcome fell by 30% [8], supporting the class-wide recommendation to measure UACR before and during SGLT2 therapy.

Hemoglobin A1c. Most commercial prior authorization forms in Tennessee require a documented A1c of 7.0% or above, plus evidence of metformin use or a documented reason for metformin intolerance, before approving Jardiance for a diabetes indication [see framework below]. The ADA defines target A1c for most non-pregnant adults as below 7.0%, with individualization based on hypoglycemia risk and life expectancy [4].

Additional labs that some Tennessee providers request include a complete metabolic panel (to assess liver function) and a urinalysis (to screen for existing urinary tract infection, which is a relative contraindication to starting an SGLT2 inhibitor). A thyroid panel is generally not required for empagliflozin specifically [9].

HealthRX Prior Authorization Readiness Framework for Tennessee Jardiance Requests

| Requirement | Typical Commercial Threshold | TennCare HF/CKD Threshold | |---|---|---| | Diagnosis code | E11.x (T2D) or I50.x (HF) or N18.x (CKD) | I50.x or N18.x required | | A1c (T2D indication) | ≥7.0% within 6 months | Not applicable | | Prior agent trial | Metformin ≥3 months or documented intolerance | Not applicable | | eGFR minimum | ≥30 mL/min/1.73m² | ≥20 mL/min/1.73m² (CKD label) | | UACR documentation | Recommended, not always required | Required for CKD indication | | Prescriber type | MD, DO, NP, PA | Same |

How Telehealth Prescribing Works for Jardiance in Tennessee

Telehealth prescribing of non-controlled medications is fully legal in Tennessee under the Tennessee Telehealth Access Act of 2016 and subsequent amendments [10]. A board-certified physician or NP conducts a synchronous video visit, reviews your uploaded labs, confirms your diagnosis, and sends the prescription electronically to a Tennessee pharmacy of your choice. The entire process can take under 45 minutes for a straightforward case.

Several national telehealth platforms operate in Tennessee, including HealthRX. The typical workflow is:

1. Complete an intake questionnaire covering your diagnosis history, current medications, and allergy list.
2. Upload lab results (BMP, A1c, UACR) dated within the past 6 months.
3. Attend a 15- to 20-minute video visit with a licensed Tennessee prescriber.
4. Receive an electronic prescription sent directly to your pharmacy, or request a 90-day supply through a mail-order pharmacy.

If your labs are not current, many telehealth platforms will generate a standing lab order so you can get bloodwork drawn at a local Quest or LabCorp in Tennessee before the prescribing visit. Locations in Nashville, Memphis, Knoxville, Chattanooga, and Murfreesboro all have same-week appointments for a BMP plus A1c panel.

The Tennessee Board of Medical Examiners and the Tennessee Board of Nursing both recognize telehealth visits as establishing a valid prescriber-patient relationship for non-controlled medications [10]. That means a Tennessee NP practicing via telehealth can write and sign your Jardiance prescription without any physician co-signature if they hold independent practice authority.

Turnaround from completed visit to pharmacy dispense is typically one to three business days for in-network pharmacies and two to five business days for mail-order.

Jardiance Coverage and Cost in Tennessee

Coverage varies sharply by payer type.

Commercial insurance. BlueCross BlueShield of Tennessee, Cigna, Aetna, and United Healthcare all cover Jardiance on their formularies, typically at tier 3 (non-preferred brand) requiring prior authorization [11]. Step therapy requiring metformin failure is standard for the T2D indication. For heart failure and CKD indications, prior authorization criteria are generally less restrictive because the clinical evidence for those indications is strong and guidelines are unambiguous [4].

TennCare (Tennessee Medicaid). As of 2025, TennCare covers empagliflozin for heart failure (Jardiance) and for CKD, but does not cover it for type 2 diabetes glycemic management alone [12]. This is a frequent source of confusion for Tennessee patients whose primary diagnosis is T2D without a heart failure or CKD comorbidity. If you fall into that category, you will need either a commercial plan, Medicare Part D, or a manufacturer savings card.

Medicare Part D. Most Part D plans cover empagliflozin, though tier placement varies by plan. The Inflation Reduction Act drug price negotiation provisions do not yet apply to Jardiance, so out-of-pocket costs under standard Part D can reach $300-400 per month without additional assistance [13].

Manufacturer savings card. Lilly and Boehringer Ingelheim offer the Jardiance Savings Card, which reduces the monthly out-of-pocket cost to as low as $10 for commercially insured patients and $35 for uninsured patients paying cash [14]. The card is not available for federal program beneficiaries (Medicaid, Medicare, TRICARE).

GoodRx and cash pricing. Without insurance or savings card, the average retail price for Jardiance 10 mg (30 tablets) in Tennessee is approximately $550-620 per month. GoodRx and similar discount programs routinely reduce this to $480-530 at major Tennessee chains including CVS, Walgreens, Kroger Pharmacy, and Walmart Pharmacy.

Transferring a Jardiance Prescription to Tennessee

If you recently moved to Tennessee and have an active Jardiance prescription from another state, transferring it is straightforward under both pharmacy law and clinical best practices.

Tennessee pharmacy law allows a licensed Tennessee pharmacist to accept an electronic or faxed transfer of a non-controlled substance prescription from an out-of-state pharmacy, provided the original pharmacy voids its remaining refills at the time of transfer [15]. You can initiate the transfer by calling any Tennessee pharmacy with your current pharmacy's name, phone number, and prescription number. The pharmacists handle the rest.

If your out-of-state prescription has no remaining refills, you will need a new prescription from a Tennessee-licensed provider. A telehealth visit is the fastest route. Bring or upload documentation of your prior prescription (a photo of the label or a pharmacy printout works), your most recent labs, and your diagnosis records. A new provider can issue a fresh Tennessee prescription within the same visit.

Prescriptions for Jardiance are typically written for 30- or 90-day supplies with up to 11 refills (covering a full year). Tennessee pharmacies fill up to a 90-day supply at a time for maintenance medications, which reduces trip frequency and often lowers per-unit cost.

503A Pharmacy Compounding of Empagliflozin in Tennessee

Tennessee is home to multiple 503A compounding pharmacies licensed by the Tennessee Board of Pharmacy. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, these pharmacies may compound empagliflozin for an individual patient when a licensed prescriber documents a clinical need that the commercially manufactured product cannot meet [16].

Common scenarios where compounding applies include patients who cannot swallow standard tablets and require a liquid suspension, patients with documented allergies to inactive ingredients in the commercial formulation, or patients needing a dose that does not exist as a commercially approved tablet (for example, 5 mg for patients with dose-limiting side effects).

503A compounding of empagliflozin requires a patient-specific prescription. The compound is not available over the counter, and Tennessee 503A pharmacies may not produce large batches for general sale, only patient-specific preparations. The FDA does not consider commercially available empagliflozin to be in shortage, so the bar for demonstrating medical necessity for a compounded version is higher than it would be for a drug on the FDA shortage list [16].

If your prescriber believes a compounded formulation is appropriate, they must include a documented clinical rationale in the prescription. Most Tennessee 503A pharmacies can prepare a liquid empagliflozin suspension within three to five business days. Shipping within Tennessee is permitted; interstate shipping of 503A compounds is legally restricted.

What Happens if Your Prior Authorization Is Denied in Tennessee

Prior authorization denials are common on the first submission, particularly for the T2D indication. Tennessee law (Tenn. Code Ann. § 56-7-109) requires commercial insurers to complete standard prior authorization reviews within three business days and urgent requests within 24 hours [17].

If denied, your prescriber can file a formal appeal. The appeal must include a letter of medical necessity, your most recent A1c, documentation of metformin use or intolerance, and any relevant comorbidity records. Citing the 2023 ADA Standards of Care recommendation for SGLT2 inhibitors in patients with ASCVD, HF, or CKD strengthens the appeal meaningfully [4].

Tennessee also allows an external independent review if your internal appeal is denied. The Tennessee Department of Commerce and Insurance oversees this process, and external reviewers must issue a decision within 45 days for standard reviews [17].

While your appeal is pending, the Jardiance Savings Card or a 30-day cash-pay prescription can bridge the gap. Some Tennessee prescribers also offer samples from Boehringer Ingelheim to cover a 30-day period during an appeal.

Monitoring After Starting Jardiance in Tennessee

Starting Jardiance is not the end of clinical contact. The ADA recommends repeating eGFR and UACR at three to six months after starting an SGLT2 inhibitor and then annually [4]. Blood pressure should be checked at each visit, as empagliflozin produces a modest but consistent systolic blood pressure reduction of approximately 3-5 mmHg [18].

Patients must be counseled about genital mycotic infections, the most common adverse effect, occurring in roughly 10% of women and 4% of men in clinical trials [1]. Rare but serious adverse effects include euglycemic diabetic ketoacidosis (more common in type 1 diabetes and during fasting or surgical stress), Fournier gangrene, and lower-limb amputations at rates not significantly elevated versus placebo in the EMPA-REG population but elevated in CANVAS (canagliflozin) data [19]. Sick-day protocols, specifically holding empagliflozin during prolonged fasting, illness, or before elective surgery, are standard clinical guidance from the AACE [7].

The FDA label specifies that empagliflozin should be held at least three days before scheduled surgery due to ketoacidosis risk [1]. Tennessee patients undergoing elective procedures should inform both their surgeon and their Jardiance prescriber at least two weeks before their procedure date.

Annual monitoring in Tennessee can occur via telehealth follow-up visits in most cases, with labs ordered to a local draw site before the video appointment. HealthRX Tennessee patients receive automated lab reminders at 90 days and 12 months after their initial prescription.

Finding a Jardiance Provider in Tennessee

Tennessee has approximately 1,400 endocrinologists, internal medicine physicians, and family practice physicians who regularly prescribe SGLT2 inhibitors, concentrated in Nashville, Memphis, and Knoxville [20]. Wait times for a new-patient endocrinology appointment in Tennessee average 8-12 weeks, which is why telehealth has become the primary first-access point for many patients.

For established diabetes patients managed by a primary care physician, requesting an add-on Jardiance prescription at an existing appointment is often the fastest route. Bring your current lab results and a printed summary of your cardiovascular or kidney comorbidities if you have them.

For patients without an established provider, a HealthRX telehealth visit with a Tennessee-licensed prescriber can be scheduled within 24-48 hours. The prescriber reviews your intake form and labs, conducts the video visit, and sends the prescription electronically. If labs are not current, a standing lab order is issued first and the prescribing visit is scheduled after results return, typically within three business days.

The American Heart Association's 2022 guideline on heart failure management explicitly states: "SGLT2 inhibitors are recommended for patients with HFrEF to reduce hospitalization for heart failure and cardiovascular death" (Class I, Level of Evidence A) [21]. Tennessee cardiologists and heart failure specialists increasingly initiate Jardiance directly rather than deferring to endocrinology, shortening the path to treatment for cardiac patients.

Patients in rural Tennessee counties, including those in Appalachian regions with limited specialist access, should know that the Rural Health Association of Tennessee supports telehealth prescribing as equivalent standard of care for chronic disease management including diabetes and heart failure [22].

The eGFR threshold of 30 mL/min/1.73m² for initiation remains the practical floor in most Tennessee prescribing contexts. Keep your most recent BMP result no older than six months when booking any telehealth visit for empagliflozin.